Search results for "Antimetabolite"

showing 9 items of 99 documents

Gene amplification in fibroblasts from ataxia telangiectasia (AT) patients and in X-ray hypersensitive AT-like Chinese hamster mutants.

2001

In search of functions involved in the regulation of gene amplification, and given the relevance of chromosome breakage in initiating the process, we analyzed the gene amplification ability of cells hypersensitive to inducers of DNA double-strand breaks and defective in cell cycle control: two human fibroblast strains derived from patients affected by ataxia telangiectasia (AT) and two hamster mutant cell lines belonging to complementation group XRCC8 of the rodent X-ray-sensitive mutants. These mutants are considered hamster models of AT cells. To measure gene amplification, the frequency and the rate of occurrence of N-(phosphonacetyl)-L-aspartate resistant cells were determined. In both …

Phosphonoacetic AcidCancer ResearchAntimetabolites AntineoplasticMutantHamstermedicine.disease_causeRadiation ToleranceChinese hamsterCell LineAtaxia TelangiectasiaCricetulusMultienzyme ComplexesCricetinaeGene duplicationmedicineAspartate CarbamoyltransferaseAnimalsHumansDihydroorotaseMutationAspartic AcidbiologyX-RaysGenetic Complementation TestGene AmplificationGeneral MedicineCell cycleFibroblastsmedicine.diseasebiology.organism_classificationMolecular biologyDrug Resistance NeoplasmAtaxia-telangiectasiaMutationCarbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing)Chromosome breakageCarcinogenesis
researchProduct

Gemcitabine plus vinorelbine in stage IIIB or IV non-small cell lung cancer (NSCLC): A multicentre phase II clinical trial

2001

Abstract A phase II study in patients with stage IIIB/IV non-small cell lung cancer (NSCLC) was carried out to evaluate the clinical activity and toxicity of the chemotherapeutic combination of gemcitabine+vinorelbine (GEM/VNR). Forty-five patients (40 male, 5 female) with a median age of 67 years (range 37–73) and a median ECOG performance status of 1 (range 0–2) were enrolled into the trial. Twenty patients had stage IIIB (two positive supraclavicular nodes and 20 cytologically positive pleural effusion), and 25 had stage IV NSCLC. GEM 1000 mg/m 2 diluted in 250 cc 3 of normal saline was administered iv on days 1, 8, and 15, while VNR was given 30 mg/m 2 on days 1 and 8 every 4 weeks. The…

Pulmonary and Respiratory MedicineAdultMaleCancer Researchmedicine.medical_specialtyLung NeoplasmsNeutropeniaPleural effusionmedicine.drug_classnon-small cell lung cancer (NSCLC)Phases of clinical researchNeutropeniaVinorelbineVinblastineGastroenterologyAntimetaboliteDeoxycytidineInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansInfusions IntravenousAgedbusiness.industryVinorelbineMiddle Agedmedicine.diseaseSurvival AnalysisGemcitabineGemcitabineSurgeryRegimenTreatment OutcomeOncologyInjections IntravenousFemalebusinessmedicine.drug
researchProduct

Acute and delayed toxicity of gemcitabine administered during isolated lung perfusion: a preclinical dose-escalation study in pigs.

2014

BACKGROUND: Colorectal cancer is the third most commonly diagnosed cancer worldwide, with up to 25% of patients presenting with metastases at the time of diagnosis. Despite pulmonary metastasectomy many patients go on to develop pulmonary recurrence, which might be linked to the presence of lung micrometastases. In this setting, the adjuvant administration of high-dose chemotherapy by isolated lung perfusion (ILP) has shown encouraging results. However, the tolerance to and efficacy of modern gemcitabine (GEM)-based chemotherapy regimens during adjuvant ILP remain unknown. We conducted a dose-escalating preclinical study to evaluate the immediate and delayed toxicity of GEM in a pig model t…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyAntimetabolites AntineoplasticLung Neoplasmsendocrine system diseasesPulmonary toxicityIsolated lung perfusionmedicine.medical_treatmentAcute Lung InjurySus scrofaDrug Evaluation PreclinicalAnesthesia GeneralGastroenterologyDeoxycytidineInternal medicinemedicineAnimalsLungChemotherapyLungDose-Response Relationship Drugbusiness.industryGeneral MedicineChemotherapy regimenGemcitabineGemcitabineDisease Models Animalmedicine.anatomical_structureAnesthesiaChemotherapy Cancer Regional PerfusionToxicityAcute DiseaseSurgeryFemaleMetastasectomyCardiology and Cardiovascular Medicinebusinessmedicine.drugEuropean journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
researchProduct

Pharmacological genome demethylation increases radiosensitivity of head and neck squamous carcinoma cells

2011

Aberrant inactivation of tumor suppressor genes by promoter hypermethylation has been recognized as a crucial step of tumor development and is related to aggressiveness and therapy resistance. To identify potential novel treatment strategies, we evaluated pharmacological genome demethylation for the increase of irradiation treatment effectiveness in head and neck squamous cell carcinoma (HNSCC) in this in vitro study. HNSCC cells were cultured with 2 different concentrations of 5-azacytidine (5-Aza) for 72 h, followed by a single fraction irradiation with 4 or 50 Gy, respectively. To show successful genome demethylation, the methylation status of the tumor suppressor gene hic1 (hypermethyla…

Transcriptional ActivationAntimetabolites AntineoplasticTumor suppressor geneBisulfite sequencingBiologyRadiation ToleranceCell Line TumorGeneticsmedicineHumansRadiosensitivityPromoter Regions GeneticDemethylationOncogeneSquamous Cell Carcinoma of Head and NeckGeneral MedicineDNA MethylationCell cyclemedicine.diseaseHead and neck squamous-cell carcinomaSquamous carcinomaGene Expression Regulation NeoplasticHead and Neck NeoplasmsAzacitidineCarcinoma Squamous CellCancer researchInternational Journal of Molecular Medicine
researchProduct

Infectious complications in patients with myelodysplastic syndromes: A review of the literature with emphasis on patients treated with 5-azacitidine.

2017

Myelodysplastic Syndromes are oligo-clonal stem cell disorders that are associated with cytopenias in the peripheral blood. Major causes for morbidity and mortality in myelodysplastic syndromes (MDS) patients are infections mostly due to bacteria or fungi. Beside leucopenia per se in affected patients, function of white blood cells particularly that of neutrophils seems to be impaired. Here we summarize the available data on infections in MDS patients in general and particularly those treated with 5-azacitidine.

medicine.medical_specialtyAntimetabolites AntineoplasticNeutropeniaAzacitidineInfections03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesInternal medicineGranulocyte Colony-Stimulating FactormedicineHumansIn patientMortalityInfection Controlbusiness.industryMyelodysplastic syndromesHematologyGeneral MedicineAntibiotic Prophylaxismedicine.diseasePeripheral blood030220 oncology & carcinogenesisMyelodysplastic SyndromesAzacitidineStem cellMorbiditybusiness030215 immunologymedicine.drugEuropean journal of haematology
researchProduct

A single high dose of idarubicin combined with high-dose ARA-C for treatment of first relapse in childhood ‘high-risk’ acute lymphoblastic leukaemia:…

2002

The outcome of children with acute lymphoblastic leukaemia (ALL) and early relapse remains unsatisfactory. In January 1995, the AIEOP (Associazione Italiana di Oncologia ed Ematologia Pediatrica) group opened a trial for children with ALL in first isolated or combined bone marrow relapse defined at high risk according to the length of first remission and the immunophenotype. The treatment plan included the combination of a single high-dose idarubicin and high-dose cytarabine as induction therapy followed by an intensive consolidation and stem cell transplant (SCT). In total, 100 children from 16 Italian centres were enrolled; 80 out of the 99 evaluable patients (81%) achieved second complet…

medicine.medical_specialtyChemotherapybusiness.industrymedicine.drug_classmedicine.medical_treatmentHematologyHematopoietic stem cell transplantationmedicine.diseaseAntimetaboliteSurgerymedicine.anatomical_structureInternal medicineAcute lymphocytic leukemiaCytarabineMedicineIdarubicinBone marrowbusinessSurvival ratemedicine.drugBritish Journal of Haematology
researchProduct

Amsacrine with high-dose cytarabine is highly effective therapy for refractory and relapsed acute lymphoblastic leukemia in adults

1988

Abstract Thirty-six patients with relapsed acute lymphoblastic leukemia (ALL) and four with primary refractory ALL were treated with a regimen that included amsacrine, 200 mg/m2, intravenously daily for three days with cytarabine, 3 gm/m2, by infusion over three hours daily for five days. There were 27 remissions in the 36 relapsed patients and two in the four patients with primary refractory disease. Seventeen of the 23 patients with common ALL, four of the six with T-cell ALL, one of the three with B-cell ALL, and seven of eight whose cells were not characterized responded. Toxicity of this regimen was comparable to other reinduction regimens for ALL, but the side effects characteristic o…

medicine.medical_specialtyChemotherapymedicine.drug_classbusiness.industrymedicine.medical_treatmentImmunologyCell BiologyHematologymedicine.diseaseBiochemistryAntimetaboliteGastroenterologySurgeryRegimenRefractoryAcute lymphocytic leukemiaInternal medicineToxicitymedicineCytarabinebusinessAmsacrinemedicine.drugBlood
researchProduct

Adsorption of methotrexate and calcium leucovorin onto cholestyramine in vitro.

2003

Abstract Methotrexate (MTX), an antimetabolite of folic acid, is a drug widely used in the treatment of different types of cancer. When high doses are administered, it is necessary to interrupt its action by administering calcium leucovorin (CaL). The main pathway of MTX and CaL elimination in humans occurs through the kidney, but about 10% is excreted in the faeces via the bile. Drugs, foods and sorbents in intestinal lumen modify MTX and CaL reabsorption. Individual and simultaneous studies on the adsorption of MTX and CaL from aqueous phosphate buffer by cholestyramine were carried out in order to calculate the adsorption process of MTX and CaL to cholestyramine, and to characterize the …

musculoskeletal diseasesDrugAntimetabolites Antineoplasticmedicine.drug_classmedia_common.quotation_subjectCholestyramine ResinLeucovorinPharmaceutical SciencePharmacologyAntimetabolitechemistry.chemical_compoundmedicineIon-exchange resinAnion Exchange Resinsmedia_commonLeucovorin CalciumKidneyCholestyramineChromatographyChemistryHydrogen-Ion Concentrationstomatognathic diseasesmedicine.anatomical_structureMethotrexateAntifolateMethotrexateAdsorptionmedicine.drugInternational journal of pharmaceutics
researchProduct

Significant interaction between high-dose methotrexate and high-dose piperacillin-tazobactam causing reversible neurotoxicity and renal failure in an…

2020

Introduction Pharmacokinetic interaction of high-dose methotrexate (MTX) and other concomitantly administered renally secreted medicinal products may lead to insufficient methotrexate serum level decrease and significant MTX toxicity. Case report We report the case of an 18-year-old male patient treated with high-dose MTX for an osteosarcoma and with high-dose piperacillin-tazobactam at the same time. MTX serum levels were severely elevated 24 hours after the MTX infusion and did not decrease in accordance with the specific calcium folinate rescue protocol. The patient experienced renal failure accompanied by neurological symptoms, most consistent with MTX-related renal and CNS toxicity. Ma…

musculoskeletal diseasesMaleAntimetabolites AntineoplasticAdolescentBone Neoplasms030204 cardiovascular system & hematologyPharmacology03 medical and health sciences0302 clinical medicinemedicineHumansPharmacology (medical)Drug InteractionsRenal InsufficiencyPiperacillinOsteosarcomabusiness.industryNeurotoxicitymedicine.diseaseHigh dose methotrexateAnti-Bacterial AgentsMethotrexateOncology030220 oncology & carcinogenesisPiperacillin/tazobactamOsteosarcomaMethotrexateNeurotoxicity SyndromesbusinessPharmacokinetic interactionmedicine.drugJournal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
researchProduct